Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) in head-to-head trial data. The SURMOUNT-5 trial (2025) found tirzepatide reduced body weight by approximately 20.2% vs. 13.7% for semaglutide over 72 weeks. Both are FDA-approved injectable medications for chronic weight management, but they work through different receptor mechanisms, follow different dosing schedules, and carry distinct cost and tolerability profiles. The better option depends on the individual patient’s response, medical history, and access to coverage.
Tirzepatide (Zepbound)
Mean body weight reduction: 20.2% at 72 weeks (15mg, SURMOUNT-1). 47% of patients achieved 20% or more total weight loss. Dual GIP/GLP-1 mechanism.
Semaglutide (Wegovy)
Mean body weight reduction: 14.9% at 68 weeks (2.4mg, STEP-1). 32% achieved 15% or more total weight loss. GLP-1 only mechanism. SELECT CV outcomes data available.
How They Work: One Receptor vs. Two
The core pharmacologic difference between tirzepatide and semaglutide is the number of receptors each drug activates. Understanding this difference explains most of the gap in efficacy data.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut-derived hormone that slows gastric emptying, suppresses appetite signals in the hypothalamus, and stimulates glucose-dependent insulin secretion. Semaglutide is a highly optimized version of this mechanism, with a half-life extended to approximately 7 days through fatty acid conjugation, enabling once-weekly dosing.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, sometimes called a “twincretin.” It activates both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor simultaneously. GIP has distinct and complementary metabolic effects: it enhances insulin sensitivity in adipose tissue, reduces adipogenesis, and may sensitize the hypothalamic GLP-1 signaling pathway, amplifying appetite suppression beyond what GLP-1 activation alone produces.
In practice, this dual mechanism translates to deeper appetite suppression, greater reductions in caloric intake, and a steeper weight loss trajectory at equivalent treatment durations.
Semaglutide for weight loss is Wegovy (2.4mg weekly). Ozempic is the same molecule approved for type 2 diabetes. Tirzepatide for weight loss is Zepbound. Mounjaro is tirzepatide approved for type 2 diabetes. Prescribing the diabetes formulation off-label for weight management is common in clinical practice but affects insurance coverage.
Efficacy Comparison: What the Trial Data Shows
Direct comparison between tirzepatide and semaglutide requires careful reading of the evidence. Most efficacy data comes from separate trials with different populations and endpoints. The SURMOUNT-5 trial (2025) is the only published head-to-head comparison at approved weight-management doses.
Head-to-head: SURMOUNT-5 (2025)
SURMOUNT-5 randomized adults with obesity or overweight plus a weight-related comorbidity to tirzepatide (10mg or 15mg) or semaglutide 2.4mg for 72 weeks. Tirzepatide produced approximately 20.2% mean body weight reduction vs. 13.7% for semaglutide. The proportion of patients achieving 20% or more weight loss was 47% with tirzepatide vs. 22% with semaglutide. These are clinically meaningful differences across the full distribution, not just at the high end.
Individual trial benchmarks
| Trial | Drug / Dose | Duration | Mean Weight Loss | Achieved 15%+ |
|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15mg | 72 weeks | 20.2% | 57% |
| SURMOUNT-1 | Tirzepatide 10mg | 72 weeks | 19.5% | 51% |
| STEP-1 | Semaglutide 2.4mg | 68 weeks | 14.9% | 32% |
| STEP-5 | Semaglutide 2.4mg | 104 weeks | 15.2% | 34% |
| SURMOUNT-5 | Head-to-head | 72 weeks | 20.2% vs. 13.7% | 47% vs. 22% |
Side Effect Profiles: How Do They Compare?
Both medications share a core GLP-1-driven side effect profile. The main adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These occur most frequently during dose escalation and typically improve with each stable dose period.
Side Effect Comparison: Tirzepatide vs. Semaglutide
Incidence rates from pivotal trials. Direct comparison is approximate due to different trial designs.
Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Neither drug should be used in patients with a prior serious hypersensitivity reaction to the active ingredient. Pancreatitis has been reported with both agents. Stop the medication and seek immediate care for severe abdominal pain radiating to the back.
For a complete breakdown of tirzepatide’s safety profile across all doses, see our complete guide to tirzepatide side effects.
Dosing Schedules: How Each Escalation Works
Both medications are administered once weekly by subcutaneous injection into the abdomen, thigh, or upper arm. The escalation schedules differ in the number of dose steps and the maximum approved dose.
| Phase | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Starting dose | 2.5mg weekly x 4 weeks | 0.25mg weekly x 4 weeks |
| Escalation steps | 2.5 to 5 to 7.5 to 10 to 12.5 to 15mg (every 4 weeks) | 0.25 to 0.5 to 1 to 1.7 to 2.4mg (every 4 weeks) |
| Maximum dose | 15mg weekly | 2.4mg weekly |
| Time to max dose | 20 weeks minimum | 16 weeks minimum |
| Pen type | Single-dose autoinjector pen | Single-dose pen (Wegovy); multi-dose pen (Ozempic) |
| Storage | Refrigerated; room temp up to 30 days | Refrigerated; room temp up to 28 days |
Patients switching from semaglutide to tirzepatide still begin at the 2.5mg starting dose regardless of their prior semaglutide dose. The GIP receptor component requires the same adaptation period. For a detailed guide on tirzepatide’s escalation schedule, see our article on semaglutide dosing and weight management expectations.
Cardiovascular Benefits: The Evidence So Far
Cardiovascular outcome data now exists for both agents, and this is an increasingly important factor in prescribing decisions for higher-risk patients.
Semaglutide: SELECT trial (2023)
The SELECT trial enrolled 17,604 overweight or obese adults with established cardiovascular disease but without diabetes. Semaglutide 2.4mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% vs. placebo over a median follow-up of 39.8 months (Lincoff et al., NEJM, 2023). This was the first trial to demonstrate a cardiovascular benefit of a GLP-1 agonist in people without diabetes, and it resulted in an expanded FDA label for Wegovy to include reduction of cardiovascular events.
Tirzepatide: SURPASS-CVOT ongoing
The dedicated cardiovascular outcomes trial for tirzepatide (SURPASS-CVOT) was ongoing at the time of publication. Earlier SURPASS trials showed favorable cardiovascular risk factor profiles with tirzepatide, including reductions in HbA1c, blood pressure, triglycerides, and LDL-C. A powered cardiovascular outcomes trial for tirzepatide in obesity without diabetes has not yet reported.
Semaglutide currently has a stronger cardiovascular evidence base, supported by the SELECT trial outcomes data. Tirzepatide’s cardiovascular profile in this population will be clarified when SURPASS-CVOT reports. If cardiovascular risk reduction is a primary treatment goal alongside weight loss, discuss this distinction with your physician.
Cost, Access, and Insurance Coverage
For most patients in the United States, cost and insurance coverage are the dominant practical factors in choosing between these two medications. Both carry list prices above $1,000 per month without insurance, and coverage varies considerably by plan and employer.
List prices and manufacturer savings programs
Wegovy (semaglutide 2.4mg) has a list price of approximately $1,349 per month. Zepbound (tirzepatide) launched at approximately $1,059 per month, making it modestly less expensive at list price. Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer savings cards that can reduce out-of-pocket costs significantly for commercially insured patients. Patients without insurance coverage can access Zepbound vials at lower cost through Lilly’s self-pay program.
Prior authorization and step therapy
Most commercial insurers require prior authorization for both medications. Some plans require step therapy, meaning patients must try and fail on a lower-cost agent before approving a GLP-1 agonist. Medicare Part D covers Wegovy for weight management in patients with cardiovascular disease following the SELECT trial label expansion, but coverage for Zepbound under Medicare remains restricted pending cardiovascular outcomes data.
Compounded tirzepatide was available during the FDA drug shortage period (2022 to 2024). The FDA removed tirzepatide from the shortage list in early 2025, significantly restricting legal compounding. Compounded formulations are not FDA-approved. If you are using or considering a compounded product, confirm current legal status with your physician before continuing. For full guidance, see our guide to safe tirzepatide use and Black Box Warning compliance.
Last verified: March 2026. Regulatory status may change.
Which Is Right for You? A Clinical Decision Framework
The choice between tirzepatide and semaglutide is not simply “which one works better.” Several clinical and practical factors should guide the decision together with a physician.
Tirzepatide vs. Semaglutide: Clinical Decision Guide
Summary guide only. Final prescribing decision requires individual medical evaluation.
Trial averages mask substantial individual variation. Some patients lose 5% on tirzepatide; others lose 30% on semaglutide. Response at 12 to 16 weeks is a reasonable predictor of long-term outcome. Patients who have not lost at least 5% of body weight by week 16 at a therapeutic dose are unlikely to achieve meaningful long-term results on that agent and should discuss alternatives with their physician.
What Happens When You Stop Either Medication?
Weight regain after discontinuation is well-documented for both tirzepatide and semaglutide. In the STEP-4 extension trial, patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Similar patterns are emerging from tirzepatide discontinuation data. Both medications suppress appetite through receptor activation that reverses when the drug clears. The underlying drivers of weight gain return when treatment stops.
This has important implications for how both medications should be framed: as long-term chronic disease management tools, not short-term interventions. Patients considering starting either treatment should understand that ongoing use is typically required to maintain weight loss outcomes. Discussing the long-term treatment plan upfront is an important part of a supervised programme.
Get Started With a Supervised Weight Loss Programme
Advanced TRT Clinic provides physician-supervised tirzepatide and semaglutide treatment via telemedicine, including initial consultation, dose management, lab coordination, and ongoing clinical support. Availability varies by state.
